If you have been reading about Albumin binding and want a single page that covers the useful parts, this is it: definitions, context, how it is studied, and the questions that come up repeatedly.
Updated 2025-10-01. Numbers and descriptions here follow the published literature rather than marketing material.
Stability depends heavily on physical state. A lyophilized powder kept dry, desiccated, and shielded from light typically holds its integrity for months to years at minus twenty degrees Celsius, and longer at minus eighty. Once dissolved, the peptide becomes far more vulnerable, since peptide bond hydrolysis, oxidation of susceptible residues, and aggregation all proceed faster in solution. Buffers near neutral pH are generally gentler than strongly acidic or alkaline conditions. Repeated freeze-thaw cycles and exposure to air-liquid interfaces during vigorous mixing cause losses that are easy to overlook.
Verification matters because research peptides vary widely in quality. A certificate of analysis is only as reliable as the method behind it, and a single chromatographic trace reveals little about counter-ions, residual solvents, or water content. Independent laboratories commonly pair mass confirmation with chromatographic purity and, where relevant, quantify water along with acetate or trifluoroacetate content. Reported purity figures are not standardized across suppliers, so a stated value such as ninety-eight percent is not directly comparable unless the analytical method, column, and detection wavelength accompany it.
Characterization of this peptide relies on a small set of routine techniques. Reversed-phase high-performance liquid chromatography separates the target from truncated or oxidized by-products and yields a purity estimate when paired with ultraviolet detection near 214 nanometers. Mass spectrometry, either electrospray coupled to liquid chromatography or matrix-assisted laser desorption, confirms that the observed mass matches the value calculated for the expected sequence. Amino acid analysis, and enzymatic digestion followed by fragment mapping, are used when the sequence itself rather than the mass requires verification.
CJC-1295 is a synthetic peptide designed as a long-acting analogue of growth hormone-releasing hormone (GHRH). Its structure derives from the first 29 amino acids of native GHRH, a fragment often called GRF(1-29). Four substitutions were introduced to slow enzymatic breakdown and extend activity relative to the natural sequence. The compound was developed by ConjuChem as part of a broader effort to improve the pharmacokinetic profile of peptide hormones. It is studied in laboratory and clinical research settings rather than appearing as a naturally occurring substance.
Two related forms circulate in technical discussion under the same family name. The original version carries a drug affinity complex (DAC) that binds covalently to serum albumin after administration, and this linkage substantially extends circulation time. A second form, frequently written as modified GRF(1-29) or CJC-1295 without DAC, lacks that linker and clears much faster. The naming is a frequent source of confusion because the shorthand CJC-1295 can refer to either form depending on the source. Reports sometimes fail to specify which variant was studied.
| Property | Value | Notes |
|---|---|---|
| Appearance | White to off-white powder | Assessed by visual inspection under ordinary light |
| Primary analytical method | Reversed-phase liquid chromatography | Purity estimated from peak area at 214 nm |
| Confirmatory method | Mass spectrometry | Observed mass compared with calculated value |
| Powder storage temperature | Minus 20 degrees Celsius | Minus 80 for extended archival periods |
| Solution stability | Hours to days at 2 to 8 degrees Celsius | Influenced by pH, buffer, and concentration |
Lyophilized peptide powder is comparatively stable when kept dry, cold, and protected from light. Once dissolved, the molecule is vulnerable to deamidation, oxidation, and aggregation, with the rate depending on pH, buffer composition, and temperature. Alkaline conditions and repeated freeze-thaw cycles accelerate loss of the intact peptide. The methionine present in the native sequence is a known oxidation site, which is one reason it was replaced in the modified fragment. Suppliers typically recommend cold storage of solutions and use within a short window.
Analytical confirmation usually relies on reversed-phase high-performance liquid chromatography for purity and on liquid chromatography coupled to mass spectrometry for identity. Mass data reveal the expected molecular mass and can flag truncated or oxidized species. Amino acid analysis and peptide mapping provide sequence-level verification. Immunoassays are used in some biological matrices, but antibodies raised against one releasing-hormone analog may cross-react with another. Reported purity figures depend heavily on the method used, so comparisons between suppliers require matching the analytical approach.
The two variants differ dramatically in how long they persist in circulation. The form lacking the albumin-binding group has a plasma half-life measured in tens of minutes, comparable to the natural hormone fragment. The version carrying the drug affinity complex binds albumin and shows a half-life of roughly six to eight days in human studies. That figure comes from small trials that tracked hormone levels over extended periods. The physiological consequences of sustained versus pulsatile stimulation are still debated and the literature does not settle the point.
Both forms act at the pituitary receptor for growth hormone-releasing hormone and increase growth hormone output, which in turn raises insulin-like growth factor 1. A long-acting analog produces sustained rather than pulsatile stimulation, and the physiological consequences of that pattern are not fully settled. Published human data on the extended form remain limited, and much of what circulates in discussion traces to early company reports rather than independent replication. How sustained exposure affects normal feedback remains an open question.
The distinguishing feature of the DAC form is a maleimide-containing group that reacts with the free thiol of cysteine-34 on human serum albumin. This reaction forms a covalent bond without enzymatic assistance, and it takes place after the peptide enters the bloodstream. Because albumin is abundant and long-lived, the attached peptide is carried through circulation far longer than an unmodified fragment would survive. The chemistry is a deliberate pharmacokinetic strategy rather than a change to receptor activity.
Enzymatic protection is a separate mechanism from plasma protein binding. The four substitutions in the backbone reduce recognition by dipeptidyl peptidase IV, which normally cleaves the natural hormone within minutes. Without the reactive group, this resistance still yields only a short window of activity, generally reported in the range of tens of minutes. With it, reported half-lives in early human work extended to several days. The size of that gap is the main practical distinction between the two materials.
== Stability == Avobenzone is sensitive to the properties of the solvent, being relatively stable in polar protic solvents and unstable in nonpolar environments. Also, when it is irradiated with UVA light, it generates a triplet excited state in the keto form which can either cause the avobenzone to degrade or it can transfer energy to biological targets and cause deleterious effects. Avobenzone has been shown to degrade significantly in light, resulting in less protection over time. The UV-A light in a day of sunlight in a temperate climate is sufficient to break down most of the compound. Data presented to the Food and Drug Administration by the Cosmetic, Toiletry and Fragrance Association indicates a −36% change in avobenzone's UV absorbance following one hour of exposure to sunlight. For this reason, in sunscreen products, avobenzone is always formulated together with a photostabilizer, such as octocrylene. Other photostabilizers include:
==== Enteral/gastrointestinal route ==== Through the gastrointestinal tract is sometimes termed enteral or enteric administration (literally meaning 'through the intestines'). Enteral/enteric administration usually includes oral (through the mouth) and rectal (into the rectum) administration, in the sense that these are taken up by the intestines. However, uptake of drugs administered orally may also occur already in the stomach, and as such gastrointestinal (along the gastrointestinal tract) may be a more fitting term for this route of administration. Furthermore, some application locations often classified as enteral, such as sublingual (under the tongue) and sublabial or buccal (between the cheek and gums/gingiva), are taken up in the proximal part of the gastrointestinal tract without reaching the intestines. Strictly enteral administration (directly into the intestines) can be used for systemic administration, as well as local (sometimes termed topical), such as in a contrast enema, whereby contrast media are infused into the intestines for imaging. However, for the purposes of classification based on location of effects, the term enteral is reserved for substances with systemic effects.
== Metabolism == In the case of ET/SRTX binding to a receptor and creation of a receptor-ligand complexes in various tissues, a very slow pace of dissociation is observed. In experiments conducted on rats, half-time of SRTX-b in the ileum is about 7 min (with comparison of 2 hours in case of ET-3), while in the cerebellum, the t1/2 values are more than 2–3 hours for both SRTX-b and ET-1, and in case of ET-3, the dissociation rate is negligible. Iodinated SRTX-b binds specifically to preparations of atrial membranes with a maximum binding capacity of 110 fmol per mg of protein and a dissociation constant (KD) of 3–5 nM. SRTX-a, SRTX-b and STRX-c inhibit binding of iodinated SRTX-b in the atrium at mean inhibitory concentrations (IC50) of 30, 25 and 100 nM, respectively. Other binding experiments have also shown that 125I-SRTX-b recognizes sites in a rat cerebellum KD = 3.5 nM and cerebral cortex KD=0.3nM. Furthermore, it has been shown that:
Sources: en.wikipedia.org
Isobutyryl-CoA + 6 malonyl-CoA +12 NADPH + 12H+ → Isopalmitic acid + 6 CO2 12 NADP + 5 H2O + 7 CoA The difference between (straight-chain) fatty acid synthase and branch-chain fatty acid synthase is substrate specificity of the enzyme that catalyzes the reaction of acyl-CoA to acyl-ACP.
=== Protein === C3orf52 consists of a disordered region, a transmembrane region, and a major polyA site. The molecular weight is of 24.3 kDa. This protein is predicted to be localized primarily in the cytoplasm (94.1%), with specific localization to the endoplasmic reticulum (44.4%). The protein is associated with two distinct isoforms; isoform 1 is 250 amino acids long, while isoform 2 is 217 amino acids long. In human research, isoform 2 is the predominant variation found and is the most common focus for research on C3orf52. Compositional analysis has indicated that this protein is acidic in nature, with a predicted isoelectric point of 3.99. Additionally, results show a high-scoring transmembrane segment spanning amino acids 66 to 93, which is also among the protein's most hydrophobic segment. C3orf52 contains a repetitive four-amino acid motif, including a sequence reading "LELS" at amino acids 13-16 and repeating at positions 101–104, this region is not conserved among orthologs.
=== Sydney Swans === In December 2022, McVeigh joined the Sydney Swans as an assistant coach under senior coach John Longmire, then later under senior coach Dean Cox. McVeigh departed the Sydney Swans at the conclusion of the 2026 AFL season.
Several methods for predicting drug metabolism have also been proposed in the scientific literature. Due to the large number of drug properties that must be simultaneously optimized during the design process, multi-objective optimization techniques are sometimes employed. Finally because of the limitations in the current methods for prediction of activity, drug design is still very much reliant on serendipity and bounded rationality.
Sources: en.wikipedia.org
== Contraindications == Caution is required in patients having closed angle glaucoma and in patients with a predisposition to urinary retention as the medication exhibits a relatively small anticholinergic effect. Dose adjustment is required in people who have chronic kidney disease. Liver injury has also been reported. Pizotifen treatment should be discontinued if there is any clinical evidence of liver dysfunction during treatment. Caution is advised in patients having a history of epilepsy. Withdrawal symptoms like depression, tremor, nausea, anxiety, malaise, dizziness, sleep disorder and weight decrease have been reported following abrupt cessation of pizotifen. Pizotifen is contraindicated in patients who suffer from hypersensitivity to any of its components or have gastric outlet obstruction, angle-closure glaucoma, and difficulty urinating. In addition, women who are pregnant should not take pizotifen.
=== Age === Binge eating disorder is the most common eating disorder in adults. The limited amount of research that has been done on BED shows that rates of binge eating disorder are fairly comparable among men and women. The lifetime prevalence of binge eating disorder has been observed in studies to be 2.0 percent for men and 3.5 percent for women, higher than that of the commonly recognized eating disorders, anorexia nervosa and bulimia nervosa. However another systematic literature review found the prevalence average to be about 2.3% in women and about 0.3% in men. Lifetime prevalence rates for BED in women can range anywhere from 1.5 to 6 times higher than in men. One literature review found that point prevalence rates for BED vary from 0.1 percent to 24.1 percent depending on the sample. This same review also found that the 12-month prevalence rates vary between 0.1 percent to 8.8 percent. Adolescents also have a high risk of binge eating behavior. Incidence rates of 10.1 and 6.6 per 10,000 person years have been observed in male and female adolescents in the U.S., respectively.
Since about 1990, there has been a resurgence of the promotion of colloidal silver as a dietary supplement or used otherwise internally, marketed with claims of its being an essential mineral supplement, or that it can prevent or treat numerous diseases, such as cancer, diabetes, arthritis, HIV/AIDS, herpes, and tuberculosis. No medical evidence supports the effectiveness of colloidal silver for any of these claimed indications. Silver is not an essential mineral in humans; there is no dietary requirement for silver, and hence, no such thing as a silver "deficiency". There is no evidence that colloidal silver treats or prevents any medical condition, and it can cause serious and potentially irreversible side effects, such as argyria.
=== First crewed spacecraft === Focused by the commitment to a Moon landing, in January 1962 the US announced Project Gemini, a two-person spacecraft that would support the later three-person Apollo by developing the key spaceflight technologies of space rendezvous and docking of two craft, flight durations of sufficient length to go to the Moon and back, and extra-vehicular activity to perform work outside the spacecraft. Meanwhile, Korolev had planned further long-term missions for the Vostok spacecraft, and had four Vostoks in various stages of fabrication in late 1963 at his OKB-1 facilities. The Americans' announced plans for Gemini represented major advances over the Mercury and Vostok capsules, and Korolev felt the need to try to beat the Americans to many of these innovations. He had already begun designing the Vostok's replacement, the next-generation Soyuz, a multi-cosmonaut spacecraft that had at least the same capabilities as the Gemini spacecraft. Soyuz would not be available for at least three years, and it could not be called upon to deal with this new American challenge in 1964 or 1965. Political pressure in early 1964 – which some sources claim was from Khrushchev while other sources claim was from other Communist Party officials – pushed him to modify his four remaining Vostoks to beat the Americans to new space firsts in the size of flight crews, and the duration of missions.
=== Bone density === No evidence has been identified to suggest Mirena affects bone mineral density (BMD). Two small studies, limited to studying BMD in the forearm, show no decrease in BMD. One of the studies showed at seven years of use, similar BMD at the midshaft of the ulna and at the distal radius as nonusers matched by age and BMI. In addition, BMD measurements were similar to the expected values for women in the same age group as the participants. The authors of the study said their results were predictable, since it is well established that the main factor responsible for bone loss in women is hypoestrogenism, and, in agreement with previous reports, they found estradiol levels in Mirena users to be normal.
Sources: en.wikipedia.org
Mass spectrometry establishes whether the observed molecular weight matches the calculated sequence mass. Chromatographic retention and fragment mapping add further confidence about sequence and composition. A single technique alone is rarely treated as sufficient evidence of identity.
Dry powder is markedly more stable than solution and is usually held frozen and desiccated. Room temperature exposure over days degrades it more slowly than most people assume, but long-term integrity favors freezer storage. Light protection is recommended regardless of temperature.
Methods, columns, gradients, and detection wavelengths are not standardized across laboratories. Some figures describe only the main peak area at one wavelength and ignore water, salts, or counter-ions. Without stated conditions, comparing reported percentages across sources is unreliable.
No. It is a synthetic analogue modeled on the first 29 residues of human GHRH. The substitutions and any linker are laboratory modifications rather than features of the endogenous peptide.